Developer docs
API playgroundTry for free, no card

Search company profiles

Visikol

Full company profile

uuid0002kzc

Namestring
Visikol
Legal namestring
Mattek
Websiteurl
visikol.com
Company typeenum
Private
Founded yearint
1985
Descriptiontext

Visikol is a specialty contract research organization and reagent brand focused on digital pathology, 3D tissue imaging, and 3D cell culture assays for preclinical drug discovery. Its core technology centers on proprietary tissue-clearing reagents — Visikol HISTO and HISTO-M — that render intact tissues optically transparent for 3D microscopic visualization, supported by buffer reagents, brain slicer instruments, and a portfolio of pre-validated histological and immunofluorescence panels (including multiplexed biomarker detection). The company pairs these reagents with fee-for-service offerings spanning digital pathology, ML-assisted image segmentation and classification, biomarker quantification, and a comprehensive in vitro assay menu (3D HepaRG liver co-culture, blood-brain barrier permeability, hepatotoxicity, cancer drug screening, high-content screening, and toxicology).

Visikol's commercial model rests on two pillars: (1) research product sales — consumables, reagents, and HUREL hepatocytes across eight species (human, mouse, rat SD, rat WH, dog, cat, minipig, primate, rabbit) plus Micro Livers and ZooPlates — distributed via direct enterprise sales, an online store, and a global distributor network; and (2) professional services revenue from custom CRO engagements with pharmaceutical and biotechnology customers, with secondary demand from cosmetic/personal care companies (for OECD-aligned skin and eye irritation assays) and academic research institutions. Pricing is consultation-based and not publicly disclosed.

The business is now embedded within MatTek, a wholly-owned subsidiary of Sartorius AG (Frankfurt: SAR), a publicly traded global life science group. Founded in 1985 by MIT scientists, MatTek provides Visikol with established distribution, regulatory-grade assay infrastructure, and a multinational sales footprint — including US (Ashland, MA) and European operations — that a standalone sub-50-employee specialty CRO could not independently replicate. Visikol operates as the tissue clearing and advanced imaging brand within this broader Sartorius portfolio.

Short descriptiontext

Visikol is a specialty CRO and reagent brand (within MatTek/Sartorius) offering proprietary tissue-clearing reagents, 3D imaging, ML-based image analysis, and in vitro assay services to pharmaceutical, biotechnology, cosmetic, and academic customers for preclinical drug discovery.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersHampton, United States
HQ citystring
Hampton
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
tissue clearing reagents, 3D tissue imaging, digital pathology services, in vitro drug discovery, hepatocyte cell models
Industry1 code
PRIMARYHLAGAFAM
In Silico / Computational Toxicology & PK/PD Modeling
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Preclinical Services (Toxicology/Pharmacology/DMPK)
NAICS code2 codes
  • Pharmaceutical and Medicine Manufacturing3254
  • Analytical Laboratory Instrument Manufacturing334516
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Contract Research & Drug Discovery Services
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1Research Products
TypeOne Time License
Description

Sale of tissue clearing reagents (Visikol HISTO, Visikol HISTO-M), buffers, brain slicers and related consumables for life science research

mattek.com
2Histological and Imaging Services
TypeProfessional Services
Description

Fee-for-service laboratory services including digital pathology, immunofluorescent panels, and multiplex IHC analysis

mattek.com
3In Vitro Contract Research
TypeProfessional Services
Description

Drug discovery and toxicity screening services including hepatotoxicity assays, cancer drug screening, high content screening, and pharmacokinetics studies

mattek.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure
Pricing details1 tier
1Consultation-based pricing for research products and services
ModelOtherBilling cadencePay-as-you-go
Notes

Direct consultation required for pricing. US contact: +1-508-881-6771, EU contact: +421-2-3260-7401, email: support@mattek.com

mattek.com
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 record
1Visikol
Description

Tissue clearing reagents and supporting materials providing researchers with enhanced tissue characterization, including Visikol HISTO, Visikol HISTO-M, Visikol HISTO Buffers, and Visikol Brain Slicers. Also encompasses Visikol Histological Services, Visikol Image Analysis Services, Visikol In Vitro Services, and Visikol Therapeutic Areas.

mattek.com
Core offering1 text field

Visikol is a contract research organization and product brand under MatTek (a Sartorius subsidiary) that supplies proprietary tissue clearing reagents (Visikol HISTO, HISTO-M, buffers, brain slicers) and the HUREL line of multi-species hepatocyte and liver models. It also provides fee-for-service histology, multiplex immunofluorescence, machine-learning image analysis, and in vitro drug discovery assays (toxicology, cancer screening, blood-brain barrier, 3D liver co-culture) for pharmaceutical, biotechnology, cosmetic, and academic life science research customers.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Visikol is a product portfolio within Mattek (a company now part of Sartorius) offering a unified platform of tissue clearing reagents, hepatocyte products, and specialized services for in vitro drug discovery and toxicity testing. The portfolio consists of three main product lines: (1) Visikol® tissue clearing products (HISTO™, HISTO-M™, Buffers, and Brain Slicers) that enable unprecedented 3D visualization of tissues; (2) HUREL® hepatocyte products spanning multiple species (Human, Human Pool, Mouse, Rat SD, Rat WH, Dog, Cat, Minipig, Primate, Rabbit) plus Micro Livers and ZooPlates for drug metabolism and hepatotoxicity studies; and (3) Visikol services including Histological Services (digital pathology, immunofluorescence), Image Analysis Services (with machine learning capabilities), In Vitro Services (3D liver models, blood-brain barrier assays, cancer screening), and Therapeutic Area-focused drug discovery programs. These products work together to provide researchers with comprehensive human-relevant in vitro testing solutions from tissue imaging through to cellular assays and drug efficacy/toxicity assessment.

Product and service1 record
1Visikol HISTO
Scale indicator1 record

Each record includes

Type, Value, Description, Source

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

CST provides validated antibodies and IHC/IF reagents for tissue-based research — directly comparable to Visikol's pre-validated multiplex immunofluorescence panels and standard histological services for the same academic and pharma end users.

TypeDirect peer
Description

Bio-Techne sells proteins, antibodies, and reagents into pharma/biotech research labs — directly comparable to Visikol's tissue-clearing reagent catalog and HUREL hepatocyte products, with overlapping customers and a similar reagent-plus-services motion.

TypeDirect peer
Description

LifeCanvas is a tissue-clearing reagent and services specialist directly competing with Visikol HISTO/HISTO-M in the 3D tissue imaging market, serving the same pharma and academic researchers with comparable clearing chemistries.

TypeBroad incumbent
Description

PerkinElmer's life sciences segment supplies imaging reagents, high-content screening instruments, and analytics software — overlapping with Visikol's high content screening services and brain slicer/imaging workflow for pharma drug discovery.

TypeEmerging player
Description

Crown Bioscience is a preclinical CRO specializing in oncology and metabolic disease models — overlapping with Visikol's oncology drug screening, NAFLD/NASH, and 3D HepaRG liver services for similar pharma/biotech customers.

TypeBroad incumbent
Description

Charles River is a global preclinical CRO offering toxicology, DMPK, and safety assessment services that overlap directly with Visikol's in vitro hepatotoxicity and BBB permeability assays, but at much greater scale and GLP-accredited scope.

TypeDirect peer
Description

Abcam supplies research-grade antibodies and immunoassay reagents used in tissue imaging and IHC workflows that consume Visikol's clearing reagents and histological services, making it a peer in the life science research tools category.

TypeEmerging player
Description

Akoya provides multiplexed spatial tissue imaging (Opal/CODEX) and image analysis software, directly comparable to Visikol's multiplexed immunofluorescence panels and ML image analysis services for biomarker quantification in tissue.

TypeDirect peer
Description

Miltenyi offers tissue dissociation reagents, cell separation tools, and imaging reagents for cell biology research, overlapping with Visikol HISTO and Visikol's 3D cell culture assay offerings for pharma/biotech customers.

TypeEmerging player
Description

10x Genomics offers spatial transcriptomics and tissue imaging platforms (Visium, Xenium) that compete with Visikol's tissue-clearing-plus-ML workflow as an alternative way to extract spatial biology data from intact tissue samples.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability2 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature9 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds9 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors3 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Visikol

Contract Research & Drug Discovery Servicesvisikol.com

Visikol is a specialty CRO and reagent brand (within MatTek/Sartorius) offering proprietary tissue-clearing reagents, 3D imaging, ML-based image analysis, and in vitro assay services to pharmaceutical, biotechnology, cosmetic, and academic customers for preclinical drug discovery.

What Visikol does

Visikol is a specialty contract research organization and reagent brand focused on digital pathology, 3D tissue imaging, and 3D cell culture assays for preclinical drug discovery. Its core technology centers on proprietary tissue-clearing reagents — Visikol HISTO and HISTO-M — that render intact tissues optically transparent for 3D microscopic visualization, supported by buffer reagents, brain slicer instruments, and a portfolio of pre-validated histological and immunofluorescence panels (including multiplexed biomarker detection). The company pairs these reagents with fee-for-service offerings spanning digital pathology, ML-assisted image segmentation and classification, biomarker quantification, and a comprehensive in vitro assay menu (3D HepaRG liver co-culture, blood-brain barrier permeability, hepatotoxicity, cancer drug screening, high-content screening, and toxicology).

Visikol's commercial model rests on two pillars: (1) research product sales — consumables, reagents, and HUREL hepatocytes across eight species (human, mouse, rat SD, rat WH, dog, cat, minipig, primate, rabbit) plus Micro Livers and ZooPlates — distributed via direct enterprise sales, an online store, and a global distributor network; and (2) professional services revenue from custom CRO engagements with pharmaceutical and biotechnology customers, with secondary demand from cosmetic/personal care companies (for OECD-aligned skin and eye irritation assays) and academic research institutions. Pricing is consultation-based and not publicly disclosed.

The business is now embedded within MatTek, a wholly-owned subsidiary of Sartorius AG (Frankfurt: SAR), a publicly traded global life science group. Founded in 1985 by MIT scientists, MatTek provides Visikol with established distribution, regulatory-grade assay infrastructure, and a multinational sales footprint — including US (Ashland, MA) and European operations — that a standalone sub-50-employee specialty CRO could not independently replicate. Visikol operates as the tissue clearing and advanced imaging brand within this broader Sartorius portfolio.

Visikol firmographics

Firmographics
Name
Visikol
Legal name
Mattek
Website
https://visikol.com
Company type
Private
Founded year
1985
Operating status
Operating
Headcount range
1–10 employees
Short description
Visikol is a specialty CRO and reagent brand (within MatTek/Sartorius) offering proprietary tissue-clearing reagents, 3D imaging, ML-based image analysis, and in vitro assay services to pharmaceutical, biotechnology, cosmetic, and academic customers for preclinical drug discovery.
Ownership category
akta.pro rank

Visikol industry classification

Industry
Product category
Contract Research & Drug Discovery Services
NAICS
Pharmaceutical and Medicine Manufacturing (3254), Analytical Laboratory Instrument Manufacturing (334516)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAGAFAM
In Silico / Computational Toxicology & PK/PD Modeling
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Preclinical Services (Toxicology/Pharmacology/DMPK)

Keywords

  • Tissue clearing reagents
  • 3D tissue imaging
  • Digital pathology services
  • In vitro drug discovery
  • Hepatocyte cell models

Where Visikol is headquartered

Location

Headquarters

HQ city
Hampton
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Visikol business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

  1. Research Products: Sale of tissue clearing reagents (Visikol HISTO, Visikol HISTO-M), buffers, brain slicers and related consumables for life science research
  2. Histological and Imaging Services: Fee-for-service laboratory services including digital pathology, immunofluorescent panels, and multiplex IHC analysis
  3. In Vitro Contract Research: Drug discovery and toxicity screening services including hepatotoxicity assays, cancer drug screening, high content screening, and pharmacokinetics studies

Pricing tiers

ModelBillingPrice
OtherPay-as-you-goConsultation-based pricing for research products and services

Go-to-market motion1 record

Distribution channels3 records

Marketing channels4 records

Visikol product offering

Product offering

Core offering

Visikol is a contract research organization and product brand under MatTek (a Sartorius subsidiary) that supplies proprietary tissue clearing reagents (Visikol HISTO, HISTO-M, buffers, brain slicers) and the HUREL line of multi-species hepatocyte and liver models. It also provides fee-for-service histology, multiplex immunofluorescence, machine-learning image analysis, and in vitro drug discovery assays (toxicology, cancer screening, blood-brain barrier, 3D liver co-culture) for pharmaceutical, biotechnology, cosmetic, and academic life science research customers.

Product overview

Visikol is a product portfolio within Mattek (a company now part of Sartorius) offering a unified platform of tissue clearing reagents, hepatocyte products, and specialized services for in vitro drug discovery and toxicity testing. The portfolio consists of three main product lines: (1) Visikol® tissue clearing products (HISTO™, HISTO-M™, Buffers, and Brain Slicers) that enable unprecedented 3D visualization of tissues; (2) HUREL® hepatocyte products spanning multiple species (Human, Human Pool, Mouse, Rat SD, Rat WH, Dog, Cat, Minipig, Primate, Rabbit) plus Micro Livers and ZooPlates for drug metabolism and hepatotoxicity studies; and (3) Visikol services including Histological Services (digital pathology, immunofluorescence), Image Analysis Services (with machine learning capabilities), In Vitro Services (3D liver models, blood-brain barrier assays, cancer screening), and Therapeutic Area-focused drug discovery programs. These products work together to provide researchers with comprehensive human-relevant in vitro testing solutions from tissue imaging through to cellular assays and drug efficacy/toxicity assessment.

Differentiator

Problem solved

Functional benefit

Brands

  • Visikol: Tissue clearing reagents and supporting materials providing researchers with enhanced tissue characterization, including Visikol HISTO, Visikol HISTO-M, Visikol HISTO Buffers, and Visikol Brain Slicers. Also encompasses Visikol Histological Services, Visikol Image Analysis Services, Visikol In Vitro Services, and Visikol Therapeutic Areas.

Products and services

  • Visikol HISTO

Companies that use Visikol

Customer profile

Segments3 records

Ideal customer profiles3 records

Visikol technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature9 records

Visikol partnerships and signals

Strategic signal

Scale indicators1 record

Recent moves6 records

Expansion highlights5 records

Visikol competitors and assessment

Company assessment

Direct peers

  • Cell Signaling Technology: CST provides validated antibodies and IHC/IF reagents for tissue-based research — directly comparable to Visikol's pre-validated multiplex immunofluorescence panels and standard histological services for the same academic and pharma end users.
  • Bio-Techne: Bio-Techne sells proteins, antibodies, and reagents into pharma/biotech research labs — directly comparable to Visikol's tissue-clearing reagent catalog and HUREL hepatocyte products, with overlapping customers and a similar reagent-plus-services motion.
  • LifeCanvas Technologies: LifeCanvas is a tissue-clearing reagent and services specialist directly competing with Visikol HISTO/HISTO-M in the 3D tissue imaging market, serving the same pharma and academic researchers with comparable clearing chemistries.
  • Abcam: Abcam supplies research-grade antibodies and immunoassay reagents used in tissue imaging and IHC workflows that consume Visikol's clearing reagents and histological services, making it a peer in the life science research tools category.
  • Miltenyi Biotec: Miltenyi offers tissue dissociation reagents, cell separation tools, and imaging reagents for cell biology research, overlapping with Visikol HISTO and Visikol's 3D cell culture assay offerings for pharma/biotech customers.

Broad incumbents

  • PerkinElmer: PerkinElmer's life sciences segment supplies imaging reagents, high-content screening instruments, and analytics software — overlapping with Visikol's high content screening services and brain slicer/imaging workflow for pharma drug discovery.
  • Charles River Laboratories: Charles River is a global preclinical CRO offering toxicology, DMPK, and safety assessment services that overlap directly with Visikol's in vitro hepatotoxicity and BBB permeability assays, but at much greater scale and GLP-accredited scope.

Emerging players

  • Crown Bioscience: Crown Bioscience is a preclinical CRO specializing in oncology and metabolic disease models — overlapping with Visikol's oncology drug screening, NAFLD/NASH, and 3D HepaRG liver services for similar pharma/biotech customers.
  • Akoya Biosciences: Akoya provides multiplexed spatial tissue imaging (Opal/CODEX) and image analysis software, directly comparable to Visikol's multiplexed immunofluorescence panels and ML image analysis services for biomarker quantification in tissue.
  • 10x Genomics: 10x Genomics offers spatial transcriptomics and tissue imaging platforms (Visium, Xenium) that compete with Visikol's tissue-clearing-plus-ML workflow as an alternative way to extract spatial biology data from intact tissue samples.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights5 records

Customer concentration

Visikol social profiles

Digital presence

Visikol financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Visikol leadership team

Management profile

Number of profiles

Profiles3 records

Visikol funding detail

Funding detail

Funding overview

Funding rounds9 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Visikol M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Visikol

What does Visikol do?

Visikol is a contract research organization and product brand under MatTek (a Sartorius subsidiary) that supplies proprietary tissue clearing reagents (Visikol HISTO, HISTO-M, buffers, brain slicers) and the HUREL line of multi-species hepatocyte and liver models. It also provides fee-for-service histology, multiplex immunofluorescence, machine-learning image analysis, and in vitro drug discovery assays (toxicology, cancer screening, blood-brain barrier, 3D liver co-culture) for pharmaceutical, biotechnology, cosmetic, and academic life science research customers.

Is Visikol a public or private company?

Visikol is a private company. It is classified as corporate owned and is currently operating.

When was Visikol founded?

Visikol was founded in 1985. It employs 1 to 10 people.

Where is Visikol based?

Visikol is headquartered in Hampton, United States, in the North America region.

How does Visikol make money?

Three revenue lines are on record. Research Products are the primary driver. The others are histological and Imaging Services and in Vitro Contract Research.

Who are Visikol's main competitors?

Direct peers on record are Cell Signaling Technology, Bio-Techne, LifeCanvas Technologies, Abcam and Miltenyi Biotec. Broad incumbents are PerkinElmer and Charles River Laboratories. Emerging players are Crown Bioscience, Akoya Biosciences and 10x Genomics.

Does Visikol have an API?

No public API is recorded for Visikol.

What industry is Visikol in?

Visikol's product category is Contract Research & Drug Discovery Services. Its primary akta.pro industry code is HLAGAFAM, In Silico / Computational Toxicology & PK/PD Modeling. Its NAICS code is 3254 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PrwebVisikol to Expand Facility to Meet Growing Demand For ServicesVisikol expanded its Hampton, NJ facility by 11,000 sq ft, adding lab and office space. The company, spun out from Rutgers in 2016, now serves top 20 pharmaceutical companies and has accelerated growth in tissue imaging and cell culture services.Roi-njVisikol acquired by Sweden-based CELLINK for up to $19.5MCELLINK Group acquired Visikol for up to $19.5 million, paying $7.5 million in cash and debt-free terms with $12 million in potential payments. Visikol, a 3D cell culture and imaging company, will remain under current management and join CELLINK's bioprinting business area.PrwebBruker and Visikol Partner to Launch Light-Sheet Imaging ServicesVisikol partnered with Bruker to add light-sheet imaging services using the MuVi SPIM CS platform, enabling 3D imaging of larger tissues like entire mouse brains. The company will offer these services at competitive rates, with discounts for academic customers amid COVID-19 restrictions.PrwebVisikol Launches BitSlide, Cloud-Based Digital Pathology Slide Visualization PlatformVisikol launched BitSlide, a cloud-based platform for visualizing multiplex immunofluorescent whole-slide images in a web browser. The platform avoids downloading multi-gigabyte files and is hosted on AWS, with secure client access. It is being used in Visikol's service projects to share results efficiently.PrwebVisikol Expands Hampton Facility to Accommodate Service GrowthVisikol is expanding its Hampton laboratory by 2,000 sq ft to support a growing team and new services. The company reported over 50% revenue growth in 2020 and plans to double staff and operations within two years.PrwebVisikol Tissue Clearing Technology joins Corning 3D Cell Culture PortfolioVisikol announced its HISTO-M tissue clearing reagents are now commercially available through Corning as Corning 3D Clear Tissue Clearing Reagent. The reagents enable 3D imaging of 3D cell culture models with confocal microscopy, supporting drug screening and research. Visikol has used the technology in over a thousand research labs globally.GlobeNewswireFluidigm Expands Accessibility of Mass Cytometry and Imaging Mass Cytometry Technology with New Therapeutic Insights ServicesFluidigm announced its new Therapeutic Insights Services, offering mass cytometry and imaging mass cytometry services from panel design to data analysis. The company also partnered with Visikol to provide IMC access to Visikol's customers. The services aim to help researchers interrogate tissue microenvironments and support COVID-19 research.Standard BioToolsFluidigm Expands Accessibility of Mass Cytometry and Imaging Mass Cytometry Technology with New Therapeutic Insights ServicesFluidigm announced on May 7, 2020 a new Therapeutic Insights Services business offering mass cytometry and Imaging Mass Cytometry services, including panel design, antibody sourcing, staining, data acquisition and analysis. The company said over 1,000 publications cite mass cytometry, and the service targets researchers affected by COVID-19-related lab closures and those testing instruments before purchase. Fluidigm also partnered with CRO Visikol to offer IMC as a service.Stock TitanFLUIDIGM CORP (DELAWARE) Latest Stock News & Market UpdatesFluidigm Corporation reported an 8% decrease in first-quarter revenue to $27.6 million and a GAAP net loss of $16 million for the period ending in 2020. The company launched new Therapeutic Insights Services, including mass cytometry capabilities, in collaboration with Visikol to support researchers during laboratory closures caused by the pandemic.PrwebVisikol at Society of Toxicology 2020 at Booth #663Visikol will exhibit at the Society of Toxicology 2020 conference at booth #663, marking its fifth year as an exhibitor. The company will present two exhibitor-hosted sessions and a poster on 3D cell culture assays for toxicity and NASH modeling. The sessions focus on liver 3D culture and open-source models.